298 related articles for article (PubMed ID: 12907443)
1. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
Saunthararajah Y; Hillery CA; Lavelle D; Molokie R; Dorn L; Bressler L; Gavazova S; Chen YH; Hoffman R; DeSimone J
Blood; 2003 Dec; 102(12):3865-70. PubMed ID: 12907443
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
3. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
4. DNA hypo-methylating agents and sickle cell disease.
Saunthararajah Y; Lavelle D; DeSimone J
Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
[TBL] [Abstract][Full Text] [Related]
5. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
[TBL] [Abstract][Full Text] [Related]
7. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of subcutaneous decitabine in β-thalassemia intermedia.
Olivieri NF; Saunthararajah Y; Thayalasuthan V; Kwiatkowski J; Ware RE; Kuypers FA; Kim HY; Trachtenberg FL; Vichinsky EP;
Blood; 2011 Sep; 118(10):2708-11. PubMed ID: 21700776
[TBL] [Abstract][Full Text] [Related]
9. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis).
Lavelle D; Saunthararajah Y; Vaitkus K; Singh M; Banzon V; Phiasivongsva P; Redkar S; Kanekal S; Bearss D; Shi C; Inloes R; DeSimone J
J Transl Med; 2010 Oct; 8():92. PubMed ID: 20932295
[TBL] [Abstract][Full Text] [Related]
10. The role of fetal hemoglobin-enhancing agents in thalassemia.
Lal A; Vichinsky E
Semin Hematol; 2004 Oct; 41(4 Suppl 6):17-22. PubMed ID: 15534853
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.
Humphries RK; Dover G; Young NS; Moore JG; Charache S; Ley T; Nienhuis AW
J Clin Invest; 1985 Feb; 75(2):547-57. PubMed ID: 2579100
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
Atweh GF; Schechter AN
Curr Opin Hematol; 2001 Mar; 8(2):123-30. PubMed ID: 11224687
[TBL] [Abstract][Full Text] [Related]
13. Induction of fetal hemoglobin in the treatment of sickle cell disease.
Fathallah H; Atweh GF
Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
[TBL] [Abstract][Full Text] [Related]
14. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Fibach E; Prasanna P; Rodgers GP; Samid D
Blood; 1993 Oct; 82(7):2203-9. PubMed ID: 7691251
[TBL] [Abstract][Full Text] [Related]
15. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
Lavelle D; Chin J; Vaitkus K; Redkar S; Phiasivongsa P; Tang C; Will R; Hankewych M; Roxas B; Singh M; Saunthararajah Y; Desimone J
Am J Hematol; 2007 Nov; 82(11):981-5. PubMed ID: 17696208
[TBL] [Abstract][Full Text] [Related]
16. Therapies to increase fetal hemoglobin in sickle cell disease.
Steinberg MH
Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
Dover GJ; Charache SH; Boyer SH; Talbot CC; Smith KD
Prog Clin Biol Res; 1983; 134():475-88. PubMed ID: 6198661
[TBL] [Abstract][Full Text] [Related]
18.
Gilmartin AG; Groy A; Gore ER; Atkins C; Long ER; Montoute MN; Wu Z; Halsey W; McNulty DE; Ennulat D; Rueda L; Pappalardi M; Kruger RG; McCabe MT; Raoof A; Butlin R; Stowell A; Cockerill M; Waddell I; Ogilvie D; Luengo J; Jordan A; Benowitz AB
Haematologica; 2021 Jul; 106(7):1979-1987. PubMed ID: 32586904
[TBL] [Abstract][Full Text] [Related]
19. Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation.
Ruiz MA; Rivers A; Ibanez V; Vaitkus K; Mahmud N; DeSimone J; Lavelle D
Epigenetics; 2015; 10(5):397-407. PubMed ID: 25932923
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
